Replies to post #177631 on Biotech Values

[jq1234]

THRX breakup is really an annoyance! I have no idea where Theravance Biopharma will trade and it is a taxable event. Theravance Biopharma could still be interesting as it holds 85% interest in the following programs partnered with GSK: MABA, MABA/ICS, LABA/LAMA/ICS triple combo, plus its own LAMA program.